AI Medical App Passes Standard Student Test

A non-medical college student relied on Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS) Treatment mobile app when taking the Objective Structured Clinical Examination (OSCE) and scored 92%, the company announced in a news release. The app is the company's artificial intelligence (AI)-powered medical information support platform.

"The ability of the AI software to identify the pertinent positives and negatives, together with physical exam findings, and turn them into a precise description and reasoned differential diagnoses was remarkable. This is an AI tool that any medical professional can use in their pocket," Treatment.com Chief Medical Officer Dr. Kevin Peterson said in the release.

The OSCE is a standard clinical exam given at medical and nursing schools to assess students' diagnostic aptitude. It involves examining and assessing 12 simulated patients, the release explained. With the app, the student questioned each patient, summarized the findings, and indicated the most likely diagnosis. The student got 11 of the 12 most likely diagnoses correct, among them colon cancer, appendicitis, acute myocardial infarction, diabetes, and patellar tendonitis.

A suite of AI-Backed Medical Software

With a mission to "dramatically disrupt how healthcare is delivered worldwide," Treatment.com AI develops and provides medical software solutions.

"Treatment.com AI's platform is powered by its proprietary Global Library of Medicine, which incorporates AI machine learning and has been trained by hundreds of physician experts across the globe," wrote Technical Analyst Clive Maund in a February 16 report. "The company is already in partnership with the Mayo Clinic and the University of Minnesota Medical School and is in discussion with another 52 organizations."

Currently, the Vancouver, British Columbia-based firm offers three software packages. The Medical Education Library includes information and tools to help future healthcare professionals with learning and studying. The Medical Clinic Solution is a tool that delivers personalized health assessments in real-time. The Clinical Advisor Solution provides physicians with peer-reviewed information and suggested diagnoses.

High-Growth Sector

The overall AI healthcare market is projected to grow at a 37% CAGR between 2022 and 2030, by which time it will reach an estimated value of US$187 billion (US$187B), according to Statista. Roughly three years ago, in 2021, this market was valued at US$11B.

"The growth potential of this industry is enormous," Maund wrote. "With Treatment.com AI having already developed its own platform, it is centrally placed to be a part of this."

According to MarketsAndMarkets, the global AI in medical diagnostics market is expected to reach US$3.7B in value, up from US$1.3B, between 2023 and 2028, increasing at a 23.2% compound annual growth rate (CAGR).

The Catalyst: New Software Debut

The company plans to launch additional products in the healthcare marketplace this year, the company said, and any of those could boost the stock.

Maund, who conducted a technical analysis of Treatment.com AI last month, wrote in a report that the company's pattern of movement indicated a breakout from the base pattern looked likely to happen soon. He recommended the stock as a Strong Buy for all time frames.

"Treatment.com AI is a company that should have a very bright future," Maund added.

Ownership and Share Structure

According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of Treatment.com AI. They are Chief Medical Officer, Chairman and Director Dr. Kevin Peterson with 10.35% or 3.84M shares and John Fraser with 2.76% or 1.03M shares.

Retail investors own the remaining 86.88%. There are no institutional investors currently.

The company has 37.11M outstanding shares and 32.24M free float traded shares.

Its market cap is CA$17.33 million, and its 52-week trading range is CA$0.10−1.20 per share.